Why the study?
What are the pharmacokinetic properties of the oral antiarrhythmic tocainide in healthy male subjects?
What are the pharmacokinetic properties of the oral antiarrhythmic tocainide in healthy male subjects?
Answers are grounded in this paper and cite their sources.
Tocainide has excellent oral bioavailability and a long half-life, with its renal clearance being significantly dependent on urinary pH.
Tocainide, a primary amine analogue of lidocaine, is effective against some experimental and clinical arrhythmias. Its pharmacokinetic behavior was studied in 6 healthy male subjects. Peak blood levels (CB max) and area under the blood concentration-time curve (AUC) were linearly related to dose with slopes of 0.0067 mcg/ml and 6 min mcg/ml per milligram of dose, respectively. Renal clearance of tocainide averaged 59 ml/min when urinary pH was uncontrolled or acidified, while it was reduced to 13 ml/min during intense sodium bicarbonate loading. Blood levels following intravenous infusion were well described by a 2-compartment open model with a volume of the central compartment of 0.92 L/kg. The t 1/2 beta was 11 hr and total body clearance was 166 ml/min. Loo-Riegelman analysis of the absorption rate did not allow unequivocal assignment of an "order" to the absorption process. Bioavailability approached 100%. Administration of drug 5 min after a test meal suppressed CB max 40% but minimally affected AUC. Approximately 50% of the drug was found to be plasma protein bound at clinically effective concentrations.
No takes yet. Share an insight, caveat, or question.
Lalka et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: